← Eichor
Study identifier: NCT06291025 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

Condition: Thrombotic Microangiopathies  ·  Sponsor: University Hospital, Rouen

PhaseNA
Planned participants131
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Immune thrombotic thrombocytopenic purpura (iTTP) is caused by a severe, autoantibody-mediated deficiency of ADAMTS13 leading to an accumulation of ultra-large von Willebrand factor multimers in plasma and finally to microthrombi in blood vessels. The current standard of care of iTTP consists in the triple association of daily plasma exchange (PEX, 60 ml/kg/day), immunosuppressive agents and anti-adhesive treatment (Caplacizumab). Our group recently reported the outcome of 90 patients with iTTP treated with this triple association and when compared to historical patients, the triplet regimen prevented death, refractoriness and exacerbations. Likewise, plasma volumes were reduced by 2 to 3-fold and the median number of PEX sessions could be reduced from 13 to 6. PEX is an invasive and time-consuming procedure, associated with catheter and plasma-related complications ranging from 22% to 30%. Consequently, to alleviate the burden of care in iTTP, using a regimen without PEX would represent a major and topical goal. Attempts to treat patients with plasma infusion (PI) without PEX were previously reported and provided evidence that large volumes of PI (20-30 ml/kg/day) improved the initial outcome of iTTP. However, fluid overload occurred in most cases after 5-7 days, limiting the feasibility of this strategy. Nevertheless, the recent availability of caplacizumab opens the perspective of treating patients with plasma for a shorter period. Recently, strategies without PEX have bee…

This description comes directly from the study's public registry record.

Talk to the study team

Ygal Benhamou, Pr  ·  02 32 88 90 03  ·  ygal.benhamou@chu-rouen.fr

Always discuss trial participation with your own doctor first.

Locations (30)

Chu AmiensAmiens, FranceRecruiting
Chu AngersAngers, FranceRecruiting
Chru BesanonBesançon, FranceRecruiting
Chu BobignyBobigny, FranceRecruiting
Hopital Jean VerdieBondy, FranceRecruiting
Chu BordeauxBordeaux, FranceRecruiting
Chu Clermont-FerrandClermont-Ferrand, FranceRecruiting
Chu LilleLille, FranceRecruiting
Chu LimogesLimoges, FranceNot Yet Recruiting
Chu Edouard HerriotLyon, FranceRecruiting
Ap-Hm La ConceptionMarseille, FranceRecruiting
Chu MontpellierMontpellier, FranceRecruiting

+ 18 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06291025